Archemix Corp. is a privately-held biopharmaceutical company based in
Cambridge, Massachusetts. The company is leading the development of
aptamers as a new class of directed therapeutics for the prevention
and treatment of chronic and acute diseases. With their unique
properties, aptamers offer an alternative to biologics and small
molecules in numerous applications and hold extraordinary potential to
address unmet medical needs.
We have completed a Phase 1 clinical trial for our most advanced
aptamer product candidate, ARC1779, and we commenced a Phase 2a
clinical trial of ARC1779 in November 2007 in acute coronary syndrome,
or ACS. We expect to commence a Phase 2 clinical trial of ARC1779 in
January 2008 in patients suffering from a rare blood disorder known as
thrombotic thrombocytopenic purpura, or TTP.
This role will lead CMC and Quality Functions at Archemix, included
subfunctions will be Discovery, PD, Analytical, Drug Product
Manufacture, Formulations and QA.
Please contact me if you would like more information
Eric Celidonio
Contract Recruiter,
Archemix Corp.
617-475-2394
ecelidonio@[EMAIL PROTECTED]
|
